Reshaping tumor immunity by targeting SUMOylation: A novel immunotherapeutic strategy
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-09 · 1881 (4) · 189611
DOI: 10.1016/j.bbcan.2026.189611 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-09. Verfasst von Ming Yi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Changsha, China. Hauptthemen laut MEDLINE: Sumoylation, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 167 Literaturangaben. Gefördert von: Hunan Provincial Natural Science Foundation, Xiangya Hospital, Central South University.
Abstract (Originalsprache)
SUMOylation, a reversible post-translational modification mediated by Small Ubiquitin-like Modifier (SUMO) proteins, is fundamental to regulating transcriptional programs, particularly within the nucleus. Accumulating evidence indicates that SUMOylation is a critical modulator of immune signaling and inflammatory responses, with profound implications for infections, autoimmune disorders, and oncogenesis. In the context of the tumor immune microenvironment(TIME), aberrant SUMOylation activity orchestrates an immunosuppressive landscape by directly altering the function of key transcription factors in both innate and adaptive immune cells. Consequently, pharmacological inhibition of the SUMO pathway, exemplified by the first-in-class inhibitor TAK-981, has emerged as a promising therapeutic strategy. Such inhibitors can reverse immune suppression by enhancing type I interferon signaling, augmenting antigen presentation, and reinvigorating anti-tumor immunity. In this review, we synthesize current understanding of how SUMOylation governs the function and polarization of critical immune cells within the TIME, and explore the therapeutic potential of SUMO-targeting inhibitors in cancer treatment, aiming to provide novel theoretical insights and innovative strategies to advance cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Changsha, China.
- Department of Urology, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Changsha, China.
- Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, XiangYa Hospital, Central South University, Changsha, China; Key Laboratory of Carcinogenesis of National Health Commission, Can…
- Department of Radiology, The Third Xiangya Hospital of Central South University, Tongzipo Road 138, Changsha, China. Electronic address: weililx@csu.edu.cn.
Förderung
- Hunan Provincial Natural Science Foundation
- Xiangya Hospital, Central South University
Zitieren
APA
Yi, M., Wu, X., Guo, P., Yu, X., & Li, W. (2026). Reshaping tumor immunity by targeting SUMOylation: A novel immunotherapeutic strategy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(4), 189611. https://doi.org/10.1016/j.bbcan.2026.189611
Vancouver
Yi M, Wu X, Guo P, Yu X, Li W. Reshaping tumor immunity by targeting SUMOylation: A novel immunotherapeutic strategy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(4):189611. doi:10.1016/j.bbcan.2026.189611
BibTeX
@article{Yi2026,
author = {Yi, Ming and Wu, Xuecheng and Guo, Pengfei and Yu, Xinfang and Li, Wei},
title = {Reshaping tumor immunity by targeting SUMOylation: A novel immunotherapeutic strategy},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {4},
pages = {189611},
doi = {10.1016/j.bbcan.2026.189611}
}
EUVIMED